

# George J Bosl

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6148524/george-j-bosl-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169  
papers

9,354  
citations

57  
h-index

92  
g-index

175  
ext. papers

10,537  
ext. citations

5  
avg, IF

5.46  
L-index

#	Paper	IF	Citations
169	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , <b>2021</b> , 274, e1099-e1107	7.8	5
168	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , <b>2021</b> , 26, 483-491	5.7	2
167	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , <b>2021</b> , 111, 1141-1149	2.7	1
166	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
165	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1332-1337	2.2	4
164	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3074-3075	2.2	
163	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2329-2337	2.2	11
162	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience. <i>Urology</i> , <b>2019</b> , 124, 174-178	1.6	4
161	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , <b>2018</b> , 114, 133-138	1.6	6
160	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , <b>2018</b> , 118, 114-118	1.6	5
159	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e761-e769	3.2	15
158	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 837-840	2.2	10
157	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , <b>2017</b> , 103, 154-160	1.6	9
156	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3525-3528	2.2	45
155	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , <b>2017</b> , 197, 391-397	2.5	6
154	Time to publication of oncology trials and why some trials are never published. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184425	3.7	9
153	Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification. <i>Stem Cell Reports</i> , <b>2016</b> , 6, 772-783	8	6

152	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , <b>2016</b> , 95, 128-31	1.6	6
151	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2478-83	2.2	25
150	Recurrent Germ Cell Tumors: Let's Try to Cure Them All. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 445-7	3.1	1
149	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4000-4007	2.2	110
148	Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2221-5	2.2	27
147	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 453-60	3.3	3
146	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 566-72	4.9	27
145	Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. <i>Stem Cells</i> , <b>2015</b> , 33, 367-77	5.8	24
144	Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. <i>Journal of Urology</i> , <b>2015</b> , 193, 513-8	2.5	12
143	Germ cell tumors: looking to the future. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , e253-8	7.1	
142	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142846	3.7	16
141	Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3712-20	12.9	75
140	miR-18b and miR-518b Target FOXN1 during epithelial lineage differentiation in pluripotent cells. <i>Stem Cells and Development</i> , <b>2014</b> , 23, 1149-56	4.4	13
139	Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. <i>Journal of Urology</i> , <b>2014</b> , 192, 415-9	2.5	34
138	Reply: To PMID 24094653. <i>Urology</i> , <b>2013</b> , 82, 1346-7	1.6	
137	Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. <i>Urology</i> , <b>2013</b> , 82, 1341-6	1.6	16
136	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , <b>2013</b> , 119, 2574-81	6.4	21
135	Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. <i>BJU International</i> , <b>2012</b> , 110, 950-5	5.6	8

134	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. <i>Cancer</i> , <b>2012</b> , 118, 981-6	6.4	44
133	Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. <i>Urology</i> , <b>2012</b> , 79, 361-4	1.6	16
132	Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. <i>Urology</i> , <b>2012</b> , 79, 156-9	1.6	20
131	Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. <i>Urology</i> , <b>2012</b> , 79, 1079-84	1.6	5
130	Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3752-63	2.2	189
129	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , <b>2012</b> , 91, 379-83	11	20
128	Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. <i>PLoS ONE</i> , <b>2012</b> , 7, e51563	3.7	67
127	Surgery of Testicular Tumors <b>2012</b> , 871-892.e6		1
126	A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. <i>Hematology/Oncology Clinics of North America</i> , <b>2011</b> , 25, 557-76, viii -ix	3.1	10
125	Contemporary lymph node counts during primary retroperitoneal lymph node dissection. <i>Urology</i> , <b>2011</b> , 77, 368-72	1.6	12
124	Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. <i>Urology</i> , <b>2011</b> , 77, 655-9	1.6	8
123	Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1236-41	8.9	39
122	Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. <i>Cancer</i> , <b>2011</b> , 117, 1911-6	6.4	7
121	CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. <i>Radiology</i> , <b>2011</b> , 258, 41-56	20.5	143
120	Reply to S. Stenning et al and J. Lipshitz. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4211-4212	2.2	
119	Carboplatin in clinical stage I seminoma: too much and too little at the same time. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 949-52	2.2	19
118	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e740-e740	2.2	0
117	Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 519-21	2.2	13

116	TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1706-13	2.2	150
115	The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. <i>Urology</i> , <b>2010</b> , 75, 1431-5	1.6	36
114	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 523-8	4.3	55
113	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , <b>2010</b> , 116, 5243-50	6.4	20
112	Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5240-7	2.2	62
111	Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7405-11	12.9	40
110	Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. <i>Modern Pathology</i> , <b>2009</b> , 22, 1066-74	9.8	71
109	Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. <i>BJU International</i> , <b>2009</b> , 104, 1334-8	5.6	24
108	Testicular granulosa cell tumors: rare tumors need to be studied too. <i>Oncology</i> , <b>2009</b> , 23, 796	1.8	1
107	Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , <b>2008</b> , 1, 22	22.4	6
106	Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 595-600	4.7	5
105	Clinical outcome and predictors of survival in late relapse of germ cell tumor. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5524-9	2.2	84
104	Medical treatment of advanced testicular cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 672-84	27.4	253
103	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , <b>2008</b> , 112, 800-5	6.4	18
102	Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. <i>Journal of Urology</i> , <b>2007</b> , 177, 937-42; discussion 942-3	2.5	77
101	Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. <i>Stem Cells</i> , <b>2007</b> , 25, 771-8	5.8	10
100	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. <i>Cancer</i> , <b>2007</b> , 109, 528-35	6.4	60
99	Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , <b>2007</b> , 99, 993-7	5.6	25

98	Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2007</b> , 25, 487-90	4.3	20
97	Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5603-8	2.2	73
96	Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 85-90	2.2	91
95	Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 508-9		
94	Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5597-602	2.2	90
93	Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4365-9 <sup>2.2</sup>		111
92	Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 247-56	2.2	256
91	Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1033-7	2.2	69
90	830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , <b>2007</b> , 177, 277-277	2.5	6
89	Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. <i>Cancer Research</i> , <b>2006</b> , 66, 820-7 <sup>10.1</sup>		243
88	Biology and genetics of adult male germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5512-8	2.2	61
87	Advances in urologic oncology: results progress from successful interdisciplinary research. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5479-81	2.2	0
86	Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. <i>Journal of Urology</i> , <b>2006</b> , 176, 100-3; discussion 103-4	2.5	52
85	Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2006</b> , 12, 182-8	2.2	30
84	Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. <i>Journal of Urology</i> , <b>2005</b> , 174, 557-60; discussion 560	2.5	80
83	Gene expression-based classification of nonseminomatous male germ cell tumors. <i>Oncogene</i> , <b>2005</b> , 24, 5101-7	9.2	48
82	Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. <i>Functional and Integrative Genomics</i> , <b>2005</b> , 5, 59-69	3.8	20
81	Genetics and Biology of Adult Male Germ Cell Tumors <b>2005</b> , 221-229		

80	Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6549-55	2.2	283
79	Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6999-7004	2.2	61
78	Carboplatin for stage I seminoma and the sword of Damocles. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8566-9	1.7	17
77	Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9290-4	2.2	74
76	Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2781-8	2.2	153
75	Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 464-7	2.2	70
74	Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2004</b> , 22, 177-9	4.3	12
73	Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. <i>Molecular Cancer</i> , <b>2004</b> , 3, 16	42.1	107
72	Chemotherapy for teratoma with malignant transformation. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4285-91	1.72	172
71	Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2679-88	2.2	21
70	Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. <i>Journal of Urology</i> , <b>2003</b> , 170, 1159-62	2.5	50
69	Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. <i>Journal of Urology</i> , <b>2003</b> , 170, 1155-8	2.5	20
68	Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , <b>2003</b> , 62, 732-6	1.6	72
67	Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , <b>2003</b> , 62, 1092-6	1.6	19
66	Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2980-7 <sup>2</sup>	5.6	56
65	Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. <i>International Journal of Surgical Pathology</i> , <b>2002</b> , 10, 23-32	1.2	72
64	Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 365-71	5.8	80
63	Characteristic promoter hypermethylation signatures in male germ cell tumors. <i>Molecular Cancer</i> , <b>2002</b> , 1, 8	42.1	77

62	The future of therapy for nonseminomatous germ cell tumors. <i>Chest Surgery Clinics of North America</i> , <b>2002</b> , 12, 769-89		3
61	Germ Cell Tumors <b>2002</b> , 287-296		
60	Advances in the Understanding of Germ Cell Tumour Biology <b>2002</b> , 23-29		
59	Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. <i>Cell Growth &amp; Differentiation: the Molecular Biology Journal of the American Association for Cancer Research</i> , <b>2002</b> , 13, 257-64		24
58	Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2020-5	2.2	77
57	Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 682-8	2.2	84
56	Expression of ID genes in differentiated elements of human male germ cell tumors. <i>Diagnostic Molecular Pathology</i> , <b>2001</b> , 10, 248-54		3
55	Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2000</b> , 18, 265-7	4.3	8
54	Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2413-8	2.2	195
53	Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1173-80	2.2	157
52	RECOGNIZING ABNORMAL MARKER RESULTS THAT DO NOT REFLECT DISEASE IN PATIENTS WITH GERM CELL TUMORS. <i>Journal of Urology</i> , <b>2000</b> , 163, 796-801	2.5	29
51	Germ cell tumor clinical trials in North America. <i>Journal of Surgical Oncology</i> , <b>1999</b> , 17, 257-62		7
50	High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999). <i>International Journal of Cancer</i> , <b>1999</b> , 83, 834-8	7.5	7
49	A 3-Mb High-Resolution BAC/PAC Contig of 12q22 Encompassing the 830-kb Consensus Minimal Deletion in Male Germ Cell Tumors. <i>Genome Research</i> , <b>1999</b> , 9, 662-671	9.7	14
48	Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. <i>Oncogene</i> , <b>1998</b> , 16, 2345-9	9.2	133
47	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , <b>1998</b> , 17, 761-7	9.2	28
46	A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. <i>Head and Neck</i> , <b>1998</b> , 20, 497-503	4.2	39
45	Clinical stage I testis cancer: long-term outcome of patients on surveillance. <i>Journal of Urology</i> , <b>1998</b> , 159, 855-8	2.5	118



44	Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. <i>Journal of Urology</i> , <b>1998</b> , 159, 133-8	2.5	310
43	Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , <b>1997</b> , 157, 860-862	2.5	128
42	Testicular germ-cell cancer. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 242-53	59.2	720
41	Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12q22 in human male germ cell tumors. <i>Genomics</i> , <b>1996</b> , 35, 562-70	4.3	34
40	Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. <i>Head and Neck</i> , <b>1996</b> , 18, 405-11	4.2	74
39	Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>1995</b> , 13, 163-5	4.3	25
38	all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , <b>1995</b> , 76, 680-6	6.4	29
37	Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. <i>Otolaryngology - Head and Neck Surgery</i> , <b>1994</b> , 111, 31-7	5.5	48
36	Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. <i>Cancer</i> , <b>1994</b> , 73, 2520-6	6.4	63
35	Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , <b>1994</b> , 73, 2843-52	6.4	31
34	Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. <i>Cancer</i> , <b>1994</b> , 74, 1329-34	6.4	89
33	The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. <i>Journal of Urology</i> , <b>1994</b> , 152, 111-3; discussion 114	2.5	55
32	Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 60-2	9.7	89
31	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , <b>1993</b> , 72, 3313-7	6.4	20
30	Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. <i>Genes Chromosomes and Cancer</i> , <b>1993</b> , 8, 230-6	5	116
29	ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , <b>1993</b> , 20, 111-116	2.9	13
28	Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , <b>1992</b> , 10, 327-30	4.3	11
27	Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , <b>1992</b> , 5, 21-9	5	42

26	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , <b>1992</b> , 69, 550-6	6.4	91
25	Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , <b>1992</b> , 70, 2354-7	6.4	73
24	Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1991</b> , 21, 703-8	4	50
23	Abnormalities of 2q: a common genetic link between rhabdomyosarcoma and hepatoblastoma?. <i>Genes Chromosomes and Cancer</i> , <b>1991</b> , 3, 122-7	5	59
22	Two-drug therapy in patients with metastatic germ cell tumors. <i>Cancer</i> , <b>1991</b> , 67, 28-32	6.4	28
21	Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. <i>Cancer</i> , <b>1991</b> , 67, 1299-304	6.4	15
20	Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). <i>Cancer</i> , <b>1991</b> , 67, 1305-10	6.4	102
19	Extragenital and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. <i>Cancer</i> , <b>1991</b> , 67, 2049-57	6.4	87
18	Decompression of epidural metastases from germ cell tumors with chemotherapy. <i>Journal of Neuro-Oncology</i> , <b>1990</b> , 8, 275-80	4.8	30
17	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , <b>1990</b> , 65, 2465-70	6.4	28
16	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , <b>1990</b> , 66, 2476-81	6.4	103
15	Sarcoidosis, "Sarcoid-like lymphadenopathy," and testicular germ cell tumors. <i>American Journal of Medicine</i> , <b>1990</b> , 89, 651-6	2.4	22
14	Leukemic differentiation of a mediastinal germ cell tumor. <i>Genes Chromosomes and Cancer</i> , <b>1989</b> , 1, 83-75		98
13	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. <i>Journal of Urology</i> , <b>1988</b> , 139, 470-4	2.5	171
12	Abnormal colony formation and prostaglandin E responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy. <i>Cancer</i> , <b>1987</b> , 60, 312-7	6.4	3
11	Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. <i>Cancer</i> , <b>1986</b> , 57, 978-83	6.4	70
10	Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. <i>Cancer</i> , <b>1985</b> , 55, 527-34	6.4	188
9	Teratoma with malignant transformation in germ cell tumors in men. <i>Cancer</i> , <b>1985</b> , 56, 860-3	6.4	193

8	Status and prospects of the treatment of disseminated germ-cell tumors. <i>World Journal of Urology</i> , <b>1984</b> , 2, 38-42	4	3
7	VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1984</b> , 7, 327-30	2.7	29
6	Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis. <i>Cancer</i> , <b>1983</b> , 51, 2121-5	6.4	16
5	Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. <i>Urology</i> , <b>1983</b> , 21, 559-61	1.6	20
4	Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases. <i>Cancer</i> , <b>1982</b> , 50, 1591-5	6.4	32
3	Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. <i>Cancer</i> , <b>1981</b> , 47, 328-32	6.4	48
2	Tumor markers in advanced nonseminomatous testicular cancer. <i>Cancer</i> , <b>1981</b> , 47, 572-6	6.4	49
1	Malignant carcinoid of the gallbladder: third reported case and review of the literature. <i>Journal of Surgical Oncology</i> , <b>1980</b> , 13, 215-22	2.8	15